摘要
目的观察三氧化二砷与低剂量阿糖胞苷治疗老年高危骨髓增生异常综合征的临床疗效。方法选择60岁以上高危骨髓增生异常综合征患者25例MDS-RAEB-1型15例,MDS-RAEB-2型10例,随机分为两组,一组给予三氧化二砷静滴,另一组给予低剂量阿糖胞苷静滴,分别于7d、14d、21d、28d观察血象变化,于28d复查骨髓。结果三氧化二砷治疗组疗程结束后9例血象明显改善,3例无改善,复查骨髓,7例达到完全缓解,3例达部分缓解,原始细胞比例明显下降,治疗过程中耐受性好,;阿糖胞苷治疗组6例血象改善,复查骨髓,3例达完全缓解,4例部分缓解,5例未缓解,两组患者均无严重不良反应及并发症。结论三氧化二砷诱导化疗治疗老年高危骨髓增生异常综合征较传统低剂量阿糖胞苷方案缓解率高,不良反应小,患者耐受性好,治疗成本低,值得临床推广。
Objective To observe the clinical effect of arsenic trioxide and low dose of the treatment of high risk patients with high risk of bone marrow hyperplasia in elderly patients. Methods Choice over the age of 60 high risk myeloid hyperplasia abnormal syndrome patients 25 cases MDS-RAEB-1 type in 12 cases, MDS-RAEB-2 type in 8 cases, were divided for 2 groups. Group 1 received intravenous arsenic trioxide, group 1 given low dose cytarabine intravenous drip, respectively in 7 days, 14 days, 21 days ,28 days observed changes in blood and in 28 days examined the bone marrow. Result Blood of 8 cases were sig- nificantly improved after the end of the treatment of arsenic trioxide treatment, 3 cases no improvement, examined the bone mar- row, 7 cases achieved complete remission, 3 cases of partial remission, primitive cells significantly decreased the proportion, treatment process was well tolerated; cytarabine treatment group 6 cases improve the hemogram, review of bone marrow, 3 cases a- chieved complete remission, 4cases of partial remission, 5 patients had no response, two groups of patients had no serious adverse reactions and complications. Conclusion Arsenic trioxide induced chemotherapy in the treatment of elderly patients with high risk of bone marrow hyperplasia syndrome compared with the traditional low dose of the high dose of the remission rate of remission rate, patients with good tolerance, low cost of treatment, it is worth clinical promotion.
作者
吴春农
宋光彩
张杰
Wu Chunnong Song Guangcai Zhang Jie.(The first people＇s Hospital of Liangshan Yi Autonomous Prefecture, Xichang , Sichuan 615000, China)
出处
《四川医学》
CAS
2017年第1期66-68,共3页
Sichuan Medical Journal
